spondyloarthropathy: A group of inflammatory rheumatic diseases associated with arthritis and enthesitis, and often involving the axial skeleton. The most common form of spondyloarthritis is ankylosing spondylitis. Other forms include axial spondyloarthritis, peripheral spondyloarthritis, reactive arthritis, psoriatic arthritis/spondylitis and enteropathic arthritis/spondylitis.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
115 |
4. Check minimum number of eventsNone |
115 |
5. Include endpointsNone |
115 |
6. Filter based on genotype QC (FinnGen only) |
115 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M46
- Name in latin
- Osteomyelitis vertebrae
Similar endpoints
↥List of similar endpoints to
Osteomyelitis of vertebra
based on the number of shared cases.
Similar with more cases:
- Autoimmune diseases related-to ILD
- Spondylopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 937 | 363 | 565 |
| Only index persons | 806 | 323 | 483 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 63.49 | 65.55 | 62.11 |
| Only index persons | 62.54 | 64.59 | 61.16 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 115 | 40 | 75 |
| Unadjusted period prevalence (%) | 0.03 | 0.01 | 0.03 |
| Median age at first event (years) | 63.56 | 59.04 | 65.98 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 108
- Matched controls
- 1079
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M46.2
ICD-10 Finland
Osteomyelitis of vertebra
+∞
155.8
108
*
M46.3
ICD-10 Finland
Infection of intervertebral disc (pyogenic)
+∞
35.4
32
*
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
224.3
32.7
32
*
M46.4
ICD-10 Finland
Discitis, unspecified
+∞
31.8
29
*
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
78.2
26.6
29
5
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
21.3
20.3
30
19
M48.0
ICD-10 Finland
Spinal stenosis
242.7
20.3
20
*
J01MA12
ATC
levofloxacin; systemic
6.9
17.4
52
127
N02AA05
ATC
oxycodone; systemic
8.7
15.9
37
61
N03AX16
ATC
pregabalin; oral
7.4
15.8
42
85
N02AX02
ATC
tramadol; systemic, rectal
5.5
15.6
65
232
M54.5
ICD-10 Finland
Low back pain
6.5
15.1
46
111
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
172.4
14.9
15
*
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
49.9
14.6
17
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
13.8
14.5
25
23
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.1
14.4
74
321
J01FF01
ATC
clindamycin; systemic
5.5
14.3
54
167
A49.9
ICD-10 Finland
Bacterial infection, unspecified
7.9
14.0
34
59
J04AB02
ATC
rifampicin; systemic
46.4
13.6
16
*
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
+∞
12.7
12
*
M54.9
ICD-10 Finland
Dorsalgia, unspecified
11.4
12.3
23
25
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
26.5
12.0
16
7
A41.9
ICD-10 Finland
Sepsis, unspecified
12.7
11.9
21
20
N06AX21
ATC
duloxetine; oral
10.7
11.5
22
25
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
4.4
10.4
45
151
N03AX12
ATC
gabapentin; oral
7.8
9.6
22
34
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
109.2
9.6
10
*
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
+∞
9.5
9
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
+∞
9.5
9
*
UJF32
NOMESCO Finland
Coloscopy
4.2
9.4
41
136
J18.9
ICD-10 Finland
Pneumonia, unspecified
4.0
9.3
44
157
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.9
8.9
44
160
L28
ICPC
Limited function/disability (L)
5.0
8.8
30
77
A40.8
ICD-10 Finland
Other streptococcal sepsis
54.5
8.8
10
*
M54.4
ICD-10 Finland
Lumbago with sciatica
7.7
8.7
20
31
L03
ICPC
Low back symptom/complaint
4.8
8.7
31
84
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
6.6
8.6
22
40
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
48.6
7.8
9
*
C03CA01
ATC
furosemide; systemic
3.4
7.7
48
207
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
12.1
7.5
13
12
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.2
7.5
30
90
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
6.5
7.5
19
34
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.5
7.5
17
26
G06.1
ICD-10 Finland
Intraspinal abscess and granuloma
+∞
7.4
7
*
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
+∞
7.4
7
*
N02BE01
ATC
paracetamol; systemic, rectal
4.8
7.4
98
724
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
32.4
7.3
9
*
R50.9
ICD-10 Finland
Fever, unspecified
4.4
7.2
27
76
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.9
7.2
31
100
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
15.1
7.1
11
8
N02AJ06
ATC
codeine and paracetamol; systemic
3.3
7.0
45
194
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
3.0
7.0
57
291
WX408
NOMESCO Finland
General anesthesy, balanced
3.4
6.9
39
154
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
42.8
6.9
8
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
7.0
6.8
16
26
AA1AD
NOMESCO Finland
CT of head and brain
3.6
6.6
34
123
NA1AA
NOMESCO Finland
Cervical spine X-ray examination without contrast
15.6
6.5
10
7
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
74.0
6.5
7
*
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
12.1
6.5
11
10
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
28.5
6.3
8
*
A06AD11
ATC
lactulose; oral
4.4
6.3
23
63
205
Kela drug reimbursment
Chronic hypertension
3.0
6.3
43
194
NA3EA
NOMESCO Finland
Lumbar spine X-ray examination with flexion
+∞
6.3
6
*
A41.1
ICD-10 Finland
Sepsis due to other specified staphylococcus
+∞
6.3
6
*
7227C
ICD-9 Finland
Intervertebral disk disorders, Intervertebral disk disorder with myelopathy[SYNDROMA ISCHIADICUM]
+∞
6.3
6
*
J01CF02
ATC
cloxacillin; systemic
13.6
6.2
10
8
I50.9
ICD-10 Finland
Heart failure, unspecified
3.7
6.2
28
93
L08.9
ICD-10 Finland
Local infection of skin and subcutaneous tissue, unspecified
11.0
6.2
11
11
N03AE01
ATC
clonazepam; systemic
11.0
6.2
11
11
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
7.1
6.1
14
22
M03BX02
ATC
tizanidine; oral
2.7
6.1
66
394
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
16
13
14.14
16.37
10.9
6.3
13.2
9.8
mg/l
1.61
16
13
27
50
6.75
14.82
7.5
3.2
2.9
2.6
mmol/l
0.19
22
41
20
29
8.14
13.61
2.1
2.5
—
—
—
0
0
13
10
14.53
13.59
3.9
1.6
1.7
1.6
mmol/l
—
13
10
14
13
12.12
13.11
1.6
1.2
—
—
—
0
0
15
18
9.43
11.77
3.9
1.3
—
—
—
0
0
59
258
3.64
10.68
3.0
2.0
257.7
294.8
u/l
0.13
54
240
12
14
9.45
9.52
4.3
1.9
57.3
58.1
%
0.08
12
14
36
124
3.77
9.15
4.1
2.2
20.2
22.6
%
0.49
30
113
75
414
3.33
8.80
17.1
6.6
1.2
1.2
mmol/l
0.79
61
353
21
50
4.91
8.62
1.9
1.2
—
—
—
0
0
11
14
8.58
8.13
4.2
1.9
4.0
4.4
e9/l
0.25
11
14
47
211
3.08
7.65
3.3
1.9
3.3
3.1
mg/l
0.25
37
182
13
22
6.53
7.56
1.6
1.6
—
—
—
0
0
30
103
3.59
7.55
8.8
2.9
—
—
—
0
0
39
159
3.20
7.46
3.5
1.8
—
—
—
0
0
42
180
3.10
7.37
2.2
1.8
599.1
416.5
pmol/l
1.86
32
145
49
233
2.92
7.11
4.3
2.8
11147.3
4080.5
umol/l
0.28
41
202
35
139
3.18
6.95
12.1
5.3
1.1
1.1
mmol/l
0.53
35
126
14
28
5.55
6.90
2.5
1.8
—
—
—
0
0
23
71
3.80
6.71
5.0
3.3
1.2
1.2
mmol/l
2.56
23
62
61
334
2.76
6.68
5.2
2.9
—
—
—
0
0
12
22
5.97
6.44
2.7
1.8
—
—
—
0
0
38
167
2.90
6.26
2.7
1.6
1308.4
1124.2
nmol/l
0.61
28
127
11
19
6.30
6.23
1.2
1.4
—
—
—
0
0
13
27
5.30
6.14
2.5
1.8
—
—
—
0
0
61
346
2.62
6.06
4.6
2.3
161.0
166.2
ug/l
0.07
56
312
20
62
3.69
5.77
2.2
1.5
—
—
—
0
0
78
508
2.66
5.70
17.9
10.0
4.2
4.2
e9/l
0.01
73
451
11
21
5.69
5.64
1.1
2.2
—
—
—
0
0
34
148
2.84
5.64
2.6
1.7
32.3
29.2
s
2.32
34
143
61
358
2.50
5.49
7.9
3.7
50.4
39.7
ng/l
0.39
51
262
10
19
5.67
5.14
2.7
1.7
—
—
—
0
0
40
203
2.49
4.81
1.9
1.5
16.0
20.7
nmol/l
1.15
34
171
13
34
4.18
4.68
2.6
1.6
—
—
—
0
0
9
11
8.76
4.65
3.1
1.2
—
—
—
0
0
14
39
3.95
4.65
2.9
1.9
—
—
—
0
0
25
104
2.79
4.44
1.2
1.1
1.0
8.4
u/ml
—
7
45
54
324
2.26
4.36
3.0
2.3
72.0
75.8
nmol/l
0.44
47
283
61
385
2.24
4.36
6.4
3.9
—
—
—
0
0
7
6
12.30
4.33
3.4
1.2
—
—
—
0
0
15
48
3.44
4.10
2.1
2.1
1.5
1.6
g/l
0.13
15
42
7
8
9.22
3.83
3.7
1.1
—
—
—
0
0
9
16
6.00
3.74
2.9
1.8
—
—
—
0
0
9
17
5.64
3.59
3.1
1.4
—
—
—
0
0
23
103
2.54
3.51
9.8
5.1
-0.5
1.2
mmol/l
0.57
18
84
54
346
2.06
3.50
2.2
1.9
95.5
88.7
pmol/l
0.33
27
186
9
18
5.33
3.45
1.0
1.3
—
—
—
0
0
6
7
8.96
3.30
1.2
1.1
—
—
—
0
0
6
7
8.96
3.30
1.0
1.9
5.5
5.8
mg/l
—
6
7
7
11
6.69
3.23
1.1
1.5
—
—
—
0
0
9
20
4.79
3.18
2.9
1.7
—
—
—
0
0
45
280
2.00
3.09
6.4
3.4
3248.2
1534.0
ng/l
0.71
40
238
36
208
2.06
3.02
4.3
2.3
—
—
—
0
0
5
5
10.37
3.00
4.4
1.2
—
—
—
0
0
5
5
10.37
3.00
1.2
1.0
184.6
102.5
iu/ml
—
5
5
7
13
5.65
2.91
1.6
1.2
—
—
—
0
0
59
411
1.89
2.85
6.4
3.5
0.0
0.0
estimate
0.00
21
79
8
18
4.69
2.85
1.3
1.1
—
—
—
0
0
14
54
2.81
2.82
10.7
6.4
92.9
94.3
%
0.64
14
54
5
6
8.64
2.77
1.0
1.2
—
—
—
0
0
5
6
8.64
2.77
4.4
1.2
—
—
—
0
0
37
223
1.97
2.73
7.4
3.6
0.0
0.0
estimate
0.00
19
81
8
19
4.44
2.73
3.1
1.6
—
—
—
0
0
58
413
1.82
2.53
8.0
5.0
0.0
0.0
estimate
0.00
20
82
7
17
4.31
2.40
1.9
1.8
—
—
—
0
0
58
418
1.78
2.39
6.5
3.6
0.0
0.0
estimate
0.00
21
75
102
880
2.41
2.39
51.9
13.7
28.1
25.9
mg/l
0.29
95
700
23
122
2.11
2.37
1.3
1.1
15.3
28.2
iu/ml
—
6
41
21
109
2.13
2.29
3.7
1.7
—
—
—
0
0
21
110
2.11
2.23
3.8
1.8
—
—
—
0
0
23
126
2.03
2.18
9.3
4.7
104.6
104.3
mmol/l
0.13
23
121
7
20
3.66
2.09
2.3
1.2
—
—
—
0
0
47
331
1.71
2.02
7.0
3.7
—
—
—
0
0
22
123
1.98
1.97
30.5
16.8
1.3
1.2
inr
—
7
16
6
16
3.89
1.96
1.5
1.1
—
—
—
0
0
30
187
1.82
1.95
4.2
3.0
1057.8
191.0
ng/l
0.63
23
151
13
59
2.36
1.92
2.9
1.7
—
—
—
0
0
10
40
2.64
1.89
5.8
1.2
3.9
3.6
g/l
—
5
28
10
40
2.64
1.89
5.8
1.2
8.5
7.3
g/l
—
5
29
10
40
2.64
1.89
5.8
1.2
—
—
—
0
0
6
19
3.27
1.68
1.5
1.3
—
—
—
0
0
92
798
1.76
1.63
5.0
4.0
2.2
2.0
mu/l
0.39
81
697
63
500
1.57
1.59
3.4
2.7
—
—
—
0
0
5
15
3.43
1.54
1.8
1.1
—
—
—
0
0
74
613
1.58
1.52
4.3
3.3
14.9
14.9
pmol/l
0.02
66
535
23
152
1.64
1.21
1.4
1.3
1.2
1.2
u/ml
—
8
40
5
22
2.33
1.04
1.0
1.2
—
—
—
0
0
104
966
1.80
1.04
50.5
16.7
106.3
82.8
umol/l
1.63
104
966
103
955
1.75
1.02
52.9
15.6
139.3
139.6
mmol/l
0.64
103
922
55
453
1.41
1.01
4.4
5.1
1.7
3.2
ug/l
1.22
46
404
103
956
1.74
1.00
53.8
15.8
4.1
4.0
mmol/l
1.75
103
921
96
879
1.56
0.96
41.6
13.1
74.0
78.7
ml/min/173m2
0.98
91
711
8
43
1.92
0.89
2.4
2.8
4.2
4.5
pmol/l
—
8
36
30
230
1.41
0.81
1.7
1.6
1.6
1.3
mmol/l
0.84
22
187
5
23
2.23
0.77
1.2
1.3
—
—
—
0
0
5
26
1.96
0.71
1.2
1.3
—
—
—
0
0
7
43
1.67
0.68
7.0
3.0
1.6
1.5
%
—
7
43
94
883
1.35
0.56
5.6
4.5
6.3
6.1
mmol/l
0.61
81
784
90
845
1.30
0.50
8.8
6.1
43.4
40.5
mmol/mol
1.39
82
770
11
77
1.47
0.47
3.1
2.6
6.8
10.3
ug/l
0.42
11
69
6
45
1.35
0.34
1.5
2.3
—
—
—
0
0
23
266
0.83
0.29
2.2
3.0
0.7
0.9
ug/l
0.81
15
180
8
105
0.74
0.22
7.9
7.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
7.6
—
0
6
6
49
1.24
0.20
1.2
2.7
—
—
—
0
0
39
361
1.12
0.18
2.5
4.3
22.5
22.3
%
0.04
20
184
90
873
1.14
0.18
4.9
3.9
1.3
1.3
mmol/l
0.44
79
780
13
115
1.15
0.11
1.2
1.5
—
—
—
0
0
8
75
1.07
0.07
2.0
1.5
—
—
—
0
0
89
901
0.95
0.04
5.5
4.4
1.3
1.4
mmol/l
1.13
78
808
92
927
0.96
0.01
5.8
4.9
2.4
2.7
mmol/l
1.83
79
830
90
905
0.97
0.00
5.6
4.4
4.3
4.5
mmol/l
1.40
79
820
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
1261.4
—
0
5
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
2.8
—
73.7
—
0
6
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_OSTEOMYELVERTEB and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_OSTEOMYELVERTEB | 1.996 [1.5, 2.65] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.024 |
During the follow-up period (1.1.1998 — 31.12.2019), 121 out of 325 females with M13_OSTEOMYELVERTEB died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_OSTEOMYELVERTEB | 2.433 [1.84, 3.22] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 201 out of 503 males with M13_OSTEOMYELVERTEB died.
Mortality risk
Mortality risk for people of age
years, who have M13_OSTEOMYELVERTEB.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.15% | 0.363% |
| 5 | 0.982% | 2.718% |
| 10 | 2.528% | 6.78% |
| 15 | 4.728% | 12.398% |
| 20 | 8.398% | 20.461% |
Relationships between endpoints
↥Index endpoint: M13_OSTEOMYELVERTEB – Osteomyelitis of vertebra
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data